Latham & Watkins Advises Ares Management on Refinancing and Recapitalization of Zytomics Group

Latham & Watkins LLP has advised Ares Management as lender in connection with the refinancing and recapitalization of the Zytomics Group by global investment company Archimed SAS and ZytoMax GmbH.

Zytomics is a manufacturer and provider of a portfolio of clinical cancer diagnostic products and strives to equip pathologists in public institutions and private labs with products, solutions, and expertise they need to reach a precise and trustworthy cancer diagnosis. The parent company ZytoMax Holding GmbH is majority-owned by funds managed by Archimed.

Ares Management is a leading global alternative investment manager offering clients complementary primary and secondary investment solutions across credit, real estate, private equity, and infrastructure asset classes. Latham & Watkins' advice to the lender included the refinancing, in particular under an existing term and revolving financing agreement, as well as the implementation of new facilities to create a buy and build structure of the Zytomax group.

The Latham team was led by Frankfurt finance partner Alexandra Hagelüken and associate Anna-Maria Kuckerz, with Frankfurt finance partner Sibylle Münch, Paris counsel Etienne Gentil, and associate Johanna Wöerle.